Home Quality Indicator Repository Proportion of Patients With Type 2 Diabetes and Chronic Kidney Disease Who Are Prescribed Sodium/Glucose Cotransporter-2 Inhibitors

Proportion of Patients With Type 2 Diabetes and Chronic Kidney Disease Who Are Prescribed Sodium/Glucose Cotransporter-2 Inhibitors

Identifying Attributes

Care Settings
Rehabilitation Care
Country
Albania, Algeria, Armenia, Austria, Azerbaijan, Belgium, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Kosovo, Kazakhstan, Kyrgyzstan, Latvia, Lebanon, Libya, Lithuania, Luxembourg, Malta, Moldova, Montenegro, Morocco, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russian Federation, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Syria, Tunisia, Türkiye, Ukraine, United Kingdom, Channel Islands and Isle of Man, Uzbekistan
Publishing Organisation
Aktaa et al. (2022)
Type of Quality Indicator
Process
IOM Quality Dimension
Effectiveness
Domain
Person-Centredness Care

Defining Attributes

Definition

Proportion of patients with type 2 diabetes and chronic kidney disease who are prescribed sodium/glucose cotransporter-2 (SGLT2) inhibitors.

Numerator

Patients with type 2 diabetes and chronic kidney disease who are prescribed SGLT2 inhibitors.

Denominator

Patients with type 2 diabetes and chronic kidney disease who have no contraindication, refusal, or history of intolerance to SGLT2 inhibitors.

Exclusions
Use of Risk Adjustment
No
Risk Adjustments
Stratifications

Collection and Reporting Attributes

Type of Data Collection
Data Collection Methods
Frequency of Data Collection
Frequency of Data Collection in Days
Reporting Methods
Reporting Frequency
Reporting Frequency in Days
Indicator Has Recommended Targets
No

Source and Reference Attributes

Evidence Source

Aktaa S, Gencer B, Arbelo E, Davos CH, Désormais I, Hollander M, et al. European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol. 2022;29(7):1060-71.

Technical Specifications

Table 1. air.unimi.it/retrieve/8e0a9469-10e2-481e-9f22-03751b6d5f04/zwab160.pdf

Link to Measurement Tools
Quality Indicator Confirmed to be Part of a Program Used to Monitor Quality and Safety of Care Among Older People at a Population-Level between 2012-2022
No
Assessed by the Australian Consortium for Aged Care Collaborators as Generally Containing Good Properties (Importance and Scientific Acceptability)
No
Australian Consortium for Aged Care Endorsed
No
Identified by PHARMA-Care Project
No
Upload Date
02 December 2025

Contents

Actions

Date Modified 02 December 2025